Olorofim for Poorly Controlled Disseminated Coccidioidomycosis: Phase 2b Clinical Efficacy and Safety Insights
This review synthesizes key findings evaluating olorofim’s clinical effectiveness and safety in patients with refractory disseminated coccidioidomycosis, emphasizing its potential role amid limited treatment options.
Section: CardiologyJul 24, 2026
